Phase 1 Trial and Randomized, Double-blinded, Placebo-Controlled Expansion Cohort Study of Disulfiram and Gemcitabine in Solid Tumor and Pancreas Cancer Patients
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Disulfiram (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 23 Jun 2017 Planned primary completion date changed from 1 May 2021 to 5 May 2021.
- 10 Jun 2017 Biomarkers information updated
- 20 Dec 2016 Status changed from suspended to recruiting.